BioCardia, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BCDA Nasdaq 2836 www.biocardia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCardia, Inc.

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 - May 11th, 2026 3:10 pm
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways - May 8th, 2026 6:00 am
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures - Apr 28th, 2026 6:00 am
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure - Apr 20th, 2026 6:00 am
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure - Apr 2nd, 2026 8:11 am
BioCardia, Inc. Q4 2025 Earnings Call Summary - Mar 26th, 2026 6:30 am
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... - Mar 24th, 2026 9:01 pm
BioCardia Reports 2025 Business Highlights and Financial Results - Mar 24th, 2026 2:05 pm
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - Mar 19th, 2026 5:47 pm
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - Mar 17th, 2026 4:00 am
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) - Mar 3rd, 2026 6:00 am
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart - Feb 10th, 2026 7:15 am
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) - Feb 3rd, 2026 6:00 am
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - Dec 16th, 2025 6:00 am
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno - Dec 3rd, 2025 6:00 am
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - Dec 1st, 2025 6:30 am
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - Nov 24th, 2025 6:15 am
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results - Nov 12th, 2025 2:40 pm
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial - Nov 10th, 2025 6:30 am
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 - Nov 5th, 2025 5:29 pm